Chester County News and Community Website
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced significant changes to its leadership team, naming Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski succeeds Michael J. McElhaugh, …
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring Read More WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to develop a functional cure for …
Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the virtual H.C. Wainwright @ Home fireside chat series scheduled for Tuesday, December 3, 2024, at 11:00 am …
Join Arbutus Biopharma for Virtual Fireside Chat! Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising new data from its IM-PROVE I Phase 2a clinical trial, suggesting significant advancements in treatment for chronic hepatitis B …
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment Read More WARMINSTER, PA and OXFORD, United Kingdom — Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their Phase 2a IM-PROVE II clinical trial at the American Association …
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the upcoming Jefferies London Healthcare Conference, where the Company will host a fireside chat and one-on-one meetings with …
Arbutus Biopharma to Showcase Innovations at Jefferies London Healthcare Conference Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released its third-quarter 2024 financial results, showcasing significant progress in its clinical trials and a stable financial position. The company is …
Arbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) is poised to present significant findings on imdusiran, its RNAi therapeutic, during the upcoming American Association for the Study of Liver Diseases (AASLD) …
Arbutus Biopharma to Showcase Promising Imdusiran Data at Liver Conference Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) will be participating in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference, scheduled for October 8, 2024. This event gathers industry experts …
Arbutus Biopharma to Present at H.C. Wainwright Viral Hepatitis Virtual Conference Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two significant investor conferences in New York.
Arbutus Biopharma to Present at Major Investor Conferences in New York Read More